Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34461772 | 0.87 | CYP1A2 (0.35) | HCAR1ALDH1A1FAAHMGLLCYP1A2 | |
| SCHEMBL34461724 | 0.86 | GRIK1 (0.39) | HCAR1ALDH1A1FAAHMGLLKMT2A | |
| SCHEMBL34461734 | 0.82 | ALDH1A1 (0.36) | HCAR1ALDH1A1FAAHMGLLCYP1A2 | |
| SCHEMBL34461760 | 0.81 | GRIA1 (0.32) | HCAR1ALDH1A1KMT2A | |
| SCHEMBL34461723 | 0.78 | TRPA1 (0.42) | ALDH1A1CYP1A2CYP2C19KMT2ACYP3A4 | |
| SCHEMBL34461733 | 0.71 | ADORA2A (0.38) | HCAR1ALDH1A1CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL34461744 | 0.70 | ALDH1A1 (0.37) | ALDH1A1CYP1A2CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL34461729 | 0.66 | ALDH1A1 (0.35) | ALDH1A1KMT2A | |
| SCHEMBL34461739 | 0.65 | TRPA1 (0.43) | ALDH1A1KMT2A | |
| SCHEMBL29198655 | 0.59 | KMT2A (0.46) | HCAR1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2026-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | WRN, POLR1A, REV1 | HCAR1 848/4885ALDH1A1 1354/4885FAAH 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.